Format

Send to

Choose Destination
Molecules. 2017 May 3;22(5). pii: E728. doi: 10.3390/molecules22050728.

The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.

Author information

1
Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120 Halle (Saale), Germany. thomas.mueller@medizin.uni-halle.de.
2
Department of Pharmacy, University Bonn, An der Immenburg 4, 53121 Bonn, Germany. danielpfankuchen@uni-bonn.de.
3
Department of Pharmacy, University Bonn, An der Immenburg 4, 53121 Bonn, Germany. Kathleen.Wantoch@uni-bonn.de.
4
Department of Pharmacy, University Bonn, An der Immenburg 4, 53121 Bonn, Germany. martin.schlesinger@uni-bonn.de.
5
Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120 Halle (Saale), Germany. freipsch@gmail.com.
6
Department of Pharmacy, University Bonn, An der Immenburg 4, 53121 Bonn, Germany. gbendas@uni-bonn.de.

Abstract

Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH with chemoresistance is unknown. We have recently shown that LMWH reverses the cisplatin resistance of A2780cis human ovarian cancer cells in vitro. Here we address the question whether this LMWH effect is also valid under in vivo conditions. Therefore, we established tumor xenografts of A2780 and cisplatin resistant A2780cis cells in nude mice and investigated the impact of daily tinzaparin applications (10 mg/kg BW) on anti-tumor activity of cisplatin (6 mg/kg BW, weekly) considering the tumor growth kinetics. Intratumoral platinum accumulation was detected by GF-AAS. Xenografts of A2780 and A2780cis cells strongly differed in cisplatin sensitivity. As an overall consideration, tinzaparin co-treatment affected the response to cisplatin of A2780cis, but not A2780 tumors in the later experimental time range. A subgroup analysis confirmed that initially smaller A2780cis tumors benefit from tinzaparin, but also small A2780 xenografts. Tinzaparin did not affect cisplatin accumulation in A2780cis xenografts, but strongly increased the platinum content in A2780, obviously related to morphological differences in both xenografts. Although we cannot directly confirm a return of A2780cis cisplatin resistance by tinzaparin, as shown in vitro, the present findings give reason to discuss heparin effects on cytostatic drug efficiency for small tumors and warrants further investigation.

KEYWORDS:

cisplatin; low molecular weight heparin (LMWH); ovarian cancer; resistance

PMID:
28467373
PMCID:
PMC6154624
DOI:
10.3390/molecules22050728
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center